

SECTION 708A CLEANSING STATEMENT AND APPENDIX 3B

ACN 132 204 561 ABN 68 132 204 561

8-12 Alma Road, St Kilda Vic 3182

Contact:

Phone: 1300 289 697 Fax: +61 (0)3 9686 8881

Board of Directors:

Matthew Driscoll, Non- Exec Chairman Cameron Fisher, Executive Director Paul Spottiswood, Non-Exec Director Stephen Moulton, Non-Exec Director

Chief Executive Officer:

Colin Keating

Company Secretary:

Melanie Leydin

Securities on Issue:

BMP: 67,508,545 ordinary shares

Website:

http://www.buymyplace.com.au

This notice is given by buyMyplace.com.au Limited (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) the Company has issued 56,016 fully paid ordinary shares (**Shares**) at a deemed issue price of \$0.1612 (16.12 cents) per Share in relation to achievement of Short Term Incentives.
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

On behalf of the Board:

Melanie Leydin Company Secretary buyMyplace.com.au Limited

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

buyMyplace.com.au Limited

ABN

68 132 204 561

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- (a) Fully paid ordinary shares
- (b) Performance rights
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- (a) 56,016 Fully paid ordinary shares
- (b) 4,200,000 Performance rights
 Tranche 1 1,150,000 Performance rights
 Tranche 2 1,150,000 Performance rights
 Tranche 3 1,900,000 Performance rights
- 3 Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due payment; dates for if +convertible securities, the conversion price and dates for conversion)
- (a) Fully paid ordinary shares
- (b) Performance Rights

<u>Tranche 1</u> – Vesting on achievement of various revenue targets, expiring 1 January 2021.

<u>Tranche 2</u> – Vesting on achievement of various EBITDA targets, expiring 1 January 2021.

<u>Tranche 3</u> – Vesting on achievement of various share price targets, expiring 1 January 2021.

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

- (a) Yes
- (b) No upon exercise of the performance rights, securities will rank equally with existing fully paid ordinary shares

- 5 Issue price or consideration
- (a) Deemed issue price of \$0.1612 (16.12 cents) per share
- (b) Nil
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- (a) Issue of Short Term Incentive bonus shares to an employee in recognition of achievement of agreed performance objectives.
- (b) Issue of Long Term Incentive performance rights to the CEO and employees in accordance with the Performance Rights Plan.
- 6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in relation to the* +securities the subject of this Appendix 3B, and comply with section 6i

Yes

6b The date the security holder resolution under rule 7.1A was passed

24 November 2017

- 6c Number of *securities issued without security holder approval under rule 7.1
- (a) 56,016 Fully paid ordinary shares
- 6d Number of *securities issued with security holder approval under rule 7.1A

Appendix 3B Page 2 04/03/2013

Nil

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	(b) 4,200,000 Performa	ance rights
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See Annexure 1	
7	+Issue dates	9 May 2018	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.		
	2.333 followings. Refit 50 of Appendix 5D.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in	66,924,770	Fully paid ordinary shares
	section 2 if applicable)	583,775	Fully paid ordinary shares – subject to 12 months voluntary escrow

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
2,500,000	Director options exercisable at \$0.25 on or before 28 February 2021
2,500,000	Director options exercisable at \$0.30 on or before 28 February 2021
2,500,000	Director options exercisable at \$0.35 on or before 28 February 2021
1,600,000	Employee options exercisable at \$0.25 on or before 28 February 2021
1,600,000	Employee options exercisable at \$0.30 on or before 28 February 2021
1,600,000	Employee options exercisable at \$0.35 on or before 28 February 2021
625,000	Options exercisable at \$0.25 on or before 28 February 2021
625,000	Options exercisable at \$0.30 on or before 28 February 2021
625,000	Options exercisable at \$0.35 on or before 28 February 2021

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

1,875,000	Performance Rights Tranche 1, expiring 30 June 2019
1,875,000	Performance Rights Tranche 2, expiring 30 June 2019
1,875,000	Performance Rights Tranche 3, expiring 30 June 2019
600,000	Performance Rights Tranche 1, expiring 30 June 2019
600,000	Performance Rights Tranche 2, expiring 30 June 2019
600,000	Performance Rights Tranche 3, expiring 30 June 2019
625,000	Performance Rights (B) Tranche 1, expiring 30 June 2019
625,000	Performance Rights (B) Tranche 2, expiring 30 June 2019
625,000	Performance Rights (B) Tranche 3, expiring 30 June 2019
6,250,000	Options with an exercise price of \$0.16 (16 cents) exercisable from 1 January 2018 to 1 January 2021.
1,150,000	Performance Rights Tranche 1, expiring 1 January 2021

⁺ See chapter 19 for defined terms.

	Г		
		1,150,000	Performance Rights Tranche 2, expiring 1 January 2021
		1,900,000	Performance Rights Tranche 3, expiring 1 January 2021
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	
Part	t 2 - Pro rata issue		
11	Is security holder approval required?	N/A	
12	Is the issue renounceable or non-renounceable?	N/A	
13	Ratio in which the *securities will be offered	N/A	
14	*Class of *securities to which the offer relates	N/A	
15	*Record date to determine entitlements	N/A	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	N/A	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.		
19	Closing date for receipt of acceptances or renunciations	N/A	
20	Names of any underwriters	N/A	

⁺ See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

Amount of any underwriting fee or commission Names of any brokers to the issue Fee or commission payable to the broker to the issue Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders If the issue is contingent on security holders' approval, the date of the meeting Date entitlement and acceptance form and offer documents will be sent to persons entitled If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders Date rights trading will begin (if applicable) Date rights trading will begin (if applicable) Alow do security holders sell their entitlements in full through a broker? How do security holders sell part of their entitlements through a broker and accept for the balance? How do security holders dispose of their entitlements (except by sale through a broker)?			
23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders 25 If the issue is contingent on security holders' approval, the date of the meeting 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	21		N/A
the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders 25 If the issue is contingent on security holders' approval, the date of the meeting 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	22		N/A
payable to brokers who lodge acceptances or renunciations on behalf of security holders 25 If the issue is contingent on security holders' approval, the date of the meeting 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	23		N/A
security holders' approval, the date of the meeting 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	24	payable to brokers who lodge acceptances or renunciations on	N/A
acceptance form and offer documents will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	25	security holders' approval, the	N/A
and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	26	acceptance form and offer documents will be sent to	N/A
applicable) 29 Date rights trading will end (if applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	27	and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option	N/A
applicable) 30 How do security holders sell their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	28		N/A
their entitlements in full through a broker? 31 How do security holders sell part of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	29		N/A
of their entitlements through a broker and accept for the balance? 32 How do security holders dispose of their entitlements (except by sale through a broker)?	30	their entitlements in full through	N/A
of their entitlements (except by sale through a broker)?	31	of their entitlements through a broker and accept for the	N/A
33 +Issue date N/A	32	of their entitlements (except by	N/A
	33	+Issue date	N/A

⁺ See chapter 19 for defined terms.

Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities 34 Type of +securities (tick one) (a) *Securities described in Part 1 (b) All other +securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders If the *securities are *equity securities, a distribution schedule of the additional 36 *securities setting out the number of holders in the categories 1 - 1,0001,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional *securities Entities that have ticked box 34(b) 38 Number of *securities for which N/A *quotation is sought 39 +Class of +securities for which N/A quotation is sought

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	N/A	N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any
 applications received by us in relation to any *securities to be quoted and
 that no-one has any right to return any *securities to be quoted under
 sections 737, 738 or 1016F of the Corporations Act at the time that we
 request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at the
 time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

MELANIE LEYDIN
Company Secretary

9 May 2018

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	63,743,754	
Add the following:		
Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2	-	
Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval	-	
Number of partly paid *ordinary securities that became fully paid in that 12 month period	-	
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items	583,775 fully paid ordinary shares – subject to 12 months voluntary escrow – 28 July 2017	
Subtract the number of fully paid *ordinary securities cancelled during that 12 month period	-	
"A"	64,327,529	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15 [Note: this value cannot be changed]		
Multiply "A" by 0.15	9,649,129		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used			
 Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line 	8 December 2017 – Placement – 3,125,000 19 December 2017 – Options – 6,250,000 9 May 2018 – Shares – 56,016		
items "C"	9,431,016		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1			
"A" x 0.15	9,649,129		
Note: number must be same as shown in Step 2			
Subtract "C"	9,431,016		
Note: number must be same as shown in Step 3			
Total ["A" x 0.15] – "C"	218,113		
	Note: this is the remaining placement capacity under rule 7.1		

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	64,327,529	
Step 2: Calculate 10% of "A"		
"D"	0.10 Note: this value cannot be changed	
Multiply "A" by 0.10	6,432,752	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
 Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	-	
Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	6,432,752	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	6,432,752	
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.